Details for New Drug Application (NDA): 062638
✉ Email this page to a colleague
NDA 062638 describes ERYTHROCIN, which is a drug marketed by Abbott, Hospira, and Azurity, and is included in five NDAs. It is available from one supplier. Additional details are available on the ERYTHROCIN profile page.
The generic ingredient in ERYTHROCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
The generic ingredient in ERYTHROCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 062638
| Tradename: | ERYTHROCIN |
| Applicant: | Hospira |
| Ingredient: | erythromycin lactobionate |
| Patents: | 0 |
Pharmacology for NDA: 062638
| Physiological Effect | Decreased Sebaceous Gland Activity |
Suppliers and Packaging for NDA: 062638
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ERYTHROCIN | erythromycin lactobionate | INJECTABLE;INJECTION | 062638 | ANDA | Hospira, Inc. | 0409-6476 | 0409-6476-44 | 10 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-6476-44) / 100 mL in 1 VIAL, PATENT DELIVERY SYSTEM (0409-6476-54) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Oct 31, 1986 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Oct 31, 1986 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
